Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually)

Johannes Czernin¹, Lisa Bodei^{2

3}, Irvin Modlin⁴, Jeremie Calais⁵

Affiliations

¹ Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; jczernin@mednet.ucla.edu.
² Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Department of Radiology, Weill Cornell Medical College of Cornell University, New York, New York; and.
⁴ Yale University School of Medicine, New Haven, Connecticut.
⁵ Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.

Johannes Czernin et al. J Nucl Med. 2025.

. 2025 Mar 3;66(3):333-336.

doi: 10.2967/jnumed.124.269401.

Johannes Czernin¹, Lisa Bodei^{2

3}, Irvin Modlin⁴, Jeremie Calais⁵

¹ Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; jczernin@mednet.ucla.edu.
² Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Department of Radiology, Weill Cornell Medical College of Cornell University, New York, New York; and.
⁴ Yale University School of Medicine, New Haven, Connecticut.
⁵ Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.

No abstract available

LinkOut - more resources